MedTrace Logo

A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy

NCT07623187 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2026-06-03

No results posted yet for this study

Summary

The purpose of this study is to find out how well the study drug IPN60340 works to treat participants with acute myeloid leukemia. Acute myeloid leukemia is a rare blood cancer that grows quickly. This study's main aim is to compare the percentage of participants who reach complete remission within the first 6 months of treatment between the 2 study arms (study drug and standard medicines compared to placebo and standard medicines).

In this study all participants will receive azacitidine and venetoclax plus either the study drug IPN60340 or placebo. Venetoclax will be given as a tablet by mouth once each day in 28-day cycles. Azacitidine will be given by injection under the skin (subcutaneously) or through the veins (intravenously) daily for the first 7 days of each 28-day cycle. IPN60340 or placebo (depending on which arm of the study the participant is assigned to) will be given through the veins (intravenously) on day 1 of each 28-day cycle.

There will be 4 periods in this study:

* A screening period (up to 28 days) to assess whether the participant can take part requiring at least 1 visit to the study center.
* A treatment period where all eligible participants will receive azacitidine and venetoclax plus either the study drug IPN60340 or placebo. The study requires 8 visits for the first month followed by 1 visit every month until unacceptable toxicity, disease progression, the start of new cancer treatment, or study closure, whichever is first.
* A safety follow-up period (at 28 days (±3 days) after the last dose of study medicine) to assess safety after participants have finished treatment.
* A long-term follow-up period where participants' health will be monitored using a telephone call or clinic visit every 12 weeks until the end of study.

Participants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), bone marrow aspirates (sampling of the liquid part of the bone marrow). Some participants will also undergo pregnancy testing. Participants in the Phase 3 portion of the study will also be asked to fill in questionnaires.

The time each participant will be in this study will vary based on how well the medicine works to treat the participant's AML. Azacitidine and venetoclax plus either IPN60340 or placebo will be provided to participants who tolerate it for as long as their disease does not progress. Participants may withdraw consent to participate at any time.

Conditions

  • Acute Myeloid Leukaemia (AML)
  • Acute Myeloid Leukaemia

Interventions

BIOLOGICAL

IPN60340 + azacitidine + venetoclax

: IPN60340 + azacitidine + venetoclax Participants will receive: * IPN60340 per protocol by intravenous (IV) infusion in each 28-day treatment cycle * azacitidine by subcutaneous (SC) or IV daily for the first week in each 28-day treatment cycle * venetoclax orally daily every day of each 28-day treatment cycle

DRUG

Placebo + azacitidine + venetoclax

Participants will receive: * Placebo per protocol by intravenous (IV) infusion in each 28-day treatment cycle * azacitidine by subcutaneous (SC) or IV daily for the first week in each 28-day treatment cycle * venetoclax orally daily every day of each 28-day treatment cycle

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-11-01
Primary Completion
2031-05-31
Completion
2032-05-31
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07623187 on ClinicalTrials.gov